China Pharma Holdings (CPHI) Cash from Operations Growth (1y) (2011 - 2026)
China Pharma Holdings (CPHI) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | China Pharma Holdings | 41.38 Mn | 41.08 Mn | 83,566.00 | -111.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.95% |
| Dec 31, 2025 | -49.13% |
| Sep 30, 2025 | -404.74% |
| Jun 30, 2025 | 522.04% |
| Mar 31, 2025 | 87.41% |
| Dec 31, 2024 | 1,438.41% |
| Sep 30, 2024 | -104.66% |
| Jun 30, 2024 | 66.40% |
| Mar 31, 2024 | 60.14% |
| Dec 31, 2023 | -103.82% |
| Sep 30, 2023 | 359.69% |
| Jun 30, 2023 | 35.16% |
| Mar 31, 2023 | -66.95% |
| Dec 31, 2022 | 395.08% |
| Sep 30, 2022 | 148.60% |
| Jun 30, 2022 | -149.38% |
| Mar 31, 2022 | -217.58% |
| Dec 31, 2021 | -159.16% |
| Sep 30, 2021 | -100.92% |
| Jun 30, 2021 | 639.52% |